Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Short-Term Debt issuances Short-Term Debt repayments

Growth Metrics

Vycor Medical (VYCO) Divestments (2019 - 2020)

Vycor Medical has reported Divestments over the past 2 years, most recently at $9950.0 for Q3 2020.

Quarterly Divestments rose 98.01% to $9950.0 in Q3 2020 from the year-ago period, while the trailing twelve-month figure was $9574.0 through Dec 2020, changed N/A year-over-year, with the annual reading at $9574.0 for FY2020, 289.82% up from the prior year.
Divestments was $9950.0 for Q3 2020 at Vycor Medical, up from -$1226.0 in the prior quarter.
Over five years, Divestments peaked at $9950.0 in Q3 2020 and troughed at -$1226.0 in Q2 2020.